Skip to main content
ALPMY logo

Astellas Pharma Inc. (ALPMY) Stock Price & Analysis

Astellas Pharma Inc. (ALPMY) — price $17.15 (+1.18%), as of the Nov 19, 2026 trading session; market cap $30.8B.

Educational signal · not a buy or sell recommendation · How to read this

$17.15 +$0.20 (+1.18%) Market Cap $30.8B

Astellas Pharma Inc. · ALPMY · Healthcare · Drug Manufacturers - General

Astellas Pharma Inc. operates as a global pharmaceutical enterprise, specializing in the research, development, manufacturing, and commercialization of a broad spectrum of medicinal products worldwide.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • BIIB · Biogen Inc. · 37 /100
  • GSK · GSK plc · 77 /100
  • SNY · Sanofi · 87 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$17.15
Change on the day+1.18%
52-week range$12.12–$17.35
Market capitalisation$30.8B—
Price / earnings (trailing)12.67
Shares traded on the day30.4K
Beta (volatility vs the S&P 500)0.09

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $10, high $17, latest $17. $17 $10 high $17 Oct 17, 2025 Nov 19, 2026 · $17 $11Oct 17, 2025$10Oct 31, 2025$12Nov 14, 2025$13Nov 28, 2025$13Dec 12, 2025$13Dec 26, 2025$14Jan 9, 2026$14Jan 23, 2026$16Feb 6, 2026$16Feb 20, 2026$15Mar 6, 2026$15Mar 20, 2026$16Apr 2, 2026$16Apr 17, 2026$14May 1, 2026$15May 15, 2026$14May 29, 2026$13Jun 12, 2026$13Jun 26, 2026$13Jul 10, 2026$13Jul 24, 2026$15Aug 7, 2026$15Aug 21, 2026$15Sep 4, 2026$15Sep 18, 2026$14Oct 2, 2026$15Oct 16, 2026$16Oct 30, 2026$17Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Astellas Pharma (ALPMY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Undervalued
Profit Margin Moderate
Revenue Growth Moderate
Debt/Equity Neutral
ROE Moderate
Gross Margin Strong

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 9, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Astellas Pharma (ALPMY), and what does it report?

Short answer

Astellas Pharma Inc. operates as a global pharmaceutical enterprise, specializing in the research, development, manufacturing, and commercialization of a broad spectrum of medicinal products worldwide. Healthcare / Drug Manufacturers General SEC filing business address: 2-5-1, Nihonbashi-Honcho, Chuo-KU, Tokyo, M0, 103-8411. It employs 14,099 people and is led by Naoki Okamura. In Q2 FY2027 it reported revenue of ¥629.50B and net income of ¥99.93B. The market values it at $30.8B.

2 · Latest results

What do the latest results show for Astellas Pharma (ALPMY)?

Short answer · as of

The most recent reported quarter, Q2 FY2027, carried revenue of ¥629.50B. Against analyst estimates the company has EPS beat 6 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2027¥629.50B¥99.93B¥55.70 (diluted)
Q1 FY2027¥649.35B¥143.54B¥80.73 (diluted)
Q4 FY2026¥647.49B¥57.97B¥32.59 (diluted)
Q3 FY2026¥581.52B¥102.13B¥56.86 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Astellas Pharma (ALPMY)?

Short answer · as of

The distress and quality screens read Altman Z 3.68 · Piotroski F 8. Trailing ratios: ROE 20.5% · ROA 10.9% · current ratio 1.31 · earnings yield 7.8% · free-cash-flow yield 10.0%.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ALPMY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported ALPMY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Astellas Pharma (ALPMY)?

Read these with our analysis →

What Investors Ask About Astellas Pharma (ALPMY) — Healthcare

These answers are editorial: 1 of these 8 answers is drawn from the ALPMY research dossier (written Jun 15, 2026 by gpt-4o-mini); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is ALPMY a good stock to buy?

Stock Expert AI does not rate ALPMY buy, sell or hold. Astellas Pharma Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the ALPMY stock price today?

The last price recorded for Astellas Pharma Inc. (ALPMY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What does Astellas Pharma Inc. do?

Astellas Pharma Inc. is a global pharmaceutical company that engages in the manufacture, marketing, import, and export of a wide range of pharmaceutical products.

What are the key factors to evaluate for ALPMY?

Evaluate ALPMY on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Oncology Expansion: Astellas is focusing on expanding its oncology portfolio, particularly with XTANDI and XOSPATA, which cater to significant unmet medical needs. Not financial advice.

How frequently does ALPMY data refresh on this page?

ALPMY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven ALPMY's recent stock price performance?

Astellas Pharma Inc. (ALPMY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong product pipeline with innovative therapies. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider ALPMY overvalued or undervalued right now?

The trailing P/E of Astellas Pharma Inc. (ALPMY) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research ALPMY before investing?

Before investing in Astellas Pharma Inc. (ALPMY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 19 figures on this page — 1 from SEC filings and earnings calls, 14 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.